Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Sorafenib to Evaluate the Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial

NCT00758381 is registered in ClinicalTrials.gov with Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente as lead sponsor.

NCT NCT00758381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00758381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Sorafenib to Evaluate the Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial
Lead sponsor
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2007
Completion date
August 31, 2009
Enrollment
114 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer